Home > Rheumatology > EULAR 2019 > Miscellaneous > Support for tocilizumab use in giant cell arteritis

Support for tocilizumab use in giant cell arteritis

Presented By
Dr John Stone, Massachusetts General Hospital, Boston, USA
EULAR 2019
A significant proportion of patients with giant cell arteritis (GCA) remission who discontinue tocilizumab treatment after 1 year remain in clinical remission for a further 2 years. This was demonstrated in a follow-up study from the double-blind, randomised GiACTA trial [1]. Additionally, restarting tocilizumab restores clinical remission among those patients who do experience disease flare. No new safety signals were observed. In patients with GCA, the use of the interleukin-6 receptor inhibitor tocilizumab in combination with 26-week prednisone tapering resulted in higher rates of sustained glucocorticoid-free remission compared with placebo and prednisone tapering in week 52 of the GiACTA trial [2]. Dr John Stone (Massachusetts General Hospital, Boston, USA) et al. aimed to investigate longer-term efficacy and safety of tocilizumab in GCA patients in this 2-year long-term extension of the GiACTA trial. Patients in clinical remission (n=127) at t...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on